BLUE HORIZON INTERNATIONAL

Blue Horizon International (BHI) is a global healthcare consulting and innovation company specializing in adult and pediatric stem cell–based therapies. Founded in 2009, BHI operates with a unique integrated model that brings together clinical care, scientific research, and philanthropy to advance responsible regenerative medicine worldwide.

As of 2026, BHI has safely and efficiently facilitated more than 4,000 stem cell therapies globally, working with leading physicians, research institutions, and regulated facilities in compliance with internationally recognized medical and ethical standards.

BHI’s research has been published in peer-reviewed journals indexed by PubMed Central and the U.S. National Library of Medicine, and presented at leading scientific forums, including the American Academy of Orthopaedic Surgeons and the New York Academy of Sciences.

All cellular products evaluated in BHI-supported clinical studies follow Good Tissue Practice (GTP) standards and are conducted under IRB approval and Good Clinical Practice (GCP) guidelines. In the United States, the Food and Drug Administration has authorized progression along the Investigational New Drug (IND) pathway, including a registered clinical study for acute ischemic stroke (ClinicalTrials.gov Identifier: NCT03735277).

In addition to cellular therapies, BHI supports scientific research and educational initiatives involving exosomes, a rapidly evolving area of regenerative medicine. Exosome-related activities referenced by BHI are investigational, are provided for scientific and educational purposes only, and are not approved by the FDA for the diagnosis, treatment, or prevention of disease. Any exosome-related research or collaboration follows applicable regulatory requirements and ethical oversight where required.

Additional Information: More detailed information about BHI’s stem cell and exosome-related therapies can be found at www.bluehorizonstemcells.com.

Research

• Our recent research has been published in “Experimental and therapeutic medicine” cited at PubMed Central, US National Library of Medicine, National Institutes of Health; “CellR4”, the official journal of The Cure Alliance; and presented at the American Academy of Orthopedic Surgeons Annual Meeting (New Orleans, LA, 2018), Adult Stem Cells and Regenerative Medicine Conference, The New York Academy of Sciences (NY, 2019), 7th Annual German Stem Cell Network Conference (Germany, Berlin, 2019). 

• Our stem cell products evaluated in clinical studies are collected in accordance with Good Tissue Practice to ensure safety. The studies have been conducted following approval by an Investigational Research Board and in accordance with Good Clinical Practice.

• Our results show our cellular products are safe and effective in the improvement of symptoms related to chronic inflammation, spinal cord injury, stroke, musculoskeletal disorders and other medical conditions.

• The Food and Drug Administration (FDA) has given us approval to proceed with our Investigational New Drug (IND) application allowing for the initiation of a clinical study of an FDA-approved cell therapy (HCP, cord blood) for treatment of acute ischemic stroke. The study is registered at the ClinicalTrials.gov (ClinicalTrials.gov Identifier: NCT03735277).

Please click on the files below to learn more about our research:

A Retrospective Study to Evaluate the Safety of Cultured Human Wharton’s Jelly Mesenchymal Stem Cell Therapy provided at BHI Jamaica

A Retrospective Study to Evaluate the Safety of Cultured Human Wharton’s Jelly Mesenchymal Stem Cell Therapy provided at BHI Slovakia

BHI Umbilical Cord Blood

BHI Conditioned Media

BHI Adipose Tissue